{"id":10061,"date":"2026-02-24T06:42:08","date_gmt":"2026-02-24T12:42:08","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10061"},"modified":"2026-02-24T06:49:19","modified_gmt":"2026-02-24T12:49:19","slug":"nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ar\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/","title":{"rendered":"\u0633\u064a\u062a\u0645 \u0639\u0631\u0636 \u0627\u0644\u062a\u062d\u0644\u064a\u0644\u0627\u062a \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0627\u0644\u0644\u0627\u062d\u0642\u0629 \u0644\u0634\u0631\u0643\u0629 Nanoscope Therapeutics \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0628\u0642\u0639\u0629 \u0627\u0644\u0635\u0641\u0631\u0627\u0621 \u0644\u0639\u0627\u0645 2026"},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u0633\u062a\u0642\u062f\u0645 \u0627\u0644\u062f\u0643\u062a\u0648\u0631\u0629 \u0643\u0631\u064a\u0633\u062a\u064a\u0646 \u0646. \u0643\u0627\u064a \u062a\u062d\u0644\u064a\u0644\u064b\u0627 \u0645\u062a\u0639\u062f\u062f \u0627\u0644\u0645\u062a\u063a\u064a\u0631\u0627\u062a \u0644\u0628\u064a\u0627\u0646\u0627\u062a \u062f\u0631\u0627\u0633\u062a\u064a RESTORE \u0648REMAIN \u0639\u0644\u0649 \u0645\u062f\u0649 \u062b\u0644\u0627\u062b \u0633\u0646\u0648\u0627\u062a\u060c \u0644\u062a\u062d\u062f\u064a\u062f \u062e\u0635\u0627\u0626\u0635 \u0627\u0644\u0645\u0631\u0636\u0649 \u0648\u0627\u0644\u0645\u0631\u0636 \u0627\u0644\u0645\u0631\u062a\u0628\u0637\u0629 \u0628\u0623\u0641\u0636\u0644 \u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a \u0628\u0639\u062f \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062c\u064a\u0646\u064a \u0627\u0644\u0628\u0635\u0631\u064a \u0627\u0644\u0648\u0631\u0627\u062b\u064a MCO-010<\/strong><\/em><\/h3>

\u062f\u0627\u0644\u0627\u0633<\/span>,\u00a024 \u0641\u0628\u0631\u0627\u064a\u0631 2026<\/span>\u00a0 \u2014 \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u064a\u0643\u0633<\/a>, \u0623\u0639\u0644\u0646\u062a \u0634\u0631\u0643\u0629 \u0627\u0644\u062a\u0643\u0646\u0648\u0644\u0648\u062c\u064a\u0627 \u0627\u0644\u062d\u064a\u0648\u064a\u0629\u060c \u0627\u0644\u0645\u0644\u062a\u0632\u0645\u0629 \u0628\u062a\u0637\u0648\u064a\u0631 \u0648\u062a\u0633\u0648\u064a\u0642 \u0639\u0644\u0627\u062c\u0627\u062a \u062c\u062f\u064a\u062f\u0629 \u0644\u0627 \u062a\u0639\u062a\u0645\u062f \u0639\u0644\u0649 \u0646\u0648\u0639 \u0627\u0644\u0645\u0631\u0636 \u0644\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u0633\u062a\u0642\u0628\u0644\u0629 \u0644\u0644\u0636\u0648\u0621 \u0648\u0636\u0639\u0641 \u0627\u0644\u0628\u0635\u0631 \u0627\u0644\u0646\u0627\u062a\u062c \u0639\u0646 \u062a\u0646\u0643\u0633 \u0627\u0644\u0634\u0628\u0643\u064a\u0629\u060c \u0627\u0644\u064a\u0648\u0645 \u0623\u0646 \u062a\u062d\u0644\u064a\u0644\u0627\u062a \u0633\u0631\u064a\u0631\u064a\u0629 \u062c\u062f\u064a\u062f\u0629 \u0644\u0627\u062d\u0642\u0629 \u0645\u0646 \u0639\u0644\u0627\u062c\u0647\u0627 \u0627\u0644\u0631\u0627\u0626\u062f \u0641\u064a \u0645\u062c\u0627\u0644 \u0639\u0644\u0645 \u0627\u0644\u0628\u0635\u0631\u064a\u0627\u062a \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629\u060c MCO-010\u060c \u0633\u062a\u064f\u0639\u0631\u0636 \u0641\u064a\u00a0\u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u062c\u0645\u0639\u064a\u0629 \u0645\u0627\u0643\u0648\u0644\u0627 2026\u00a0<\/b>\u0633\u064a\u064f\u0639\u0642\u062f \u0641\u064a \u0627\u0644\u0641\u062a\u0631\u0629 \u0645\u0646 25 \u0625\u0644\u0649 28 \u0641\u0628\u0631\u0627\u064a\u0631 2026 \u0641\u064a<\/b>\u00a0\u0633\u0627\u0646 \u062f\u064a\u064a\u063a\u0648\u060c \u0643\u0627\u0644\u064a\u0641\u0648\u0631\u0646\u064a\u0627<\/b>.<\/p>

\u0643\u0631\u064a\u0633\u062a\u064a\u0646 \u0646. \u0643\u0627\u064a\u060c \u062f\u0643\u062a\u0648\u0631\u0627\u0647 \u0641\u064a \u0627\u0644\u0637\u0628.<\/a><\/b>, \u0633\u064a\u0642\u062f\u0645 \u0645\u062f\u064a\u0631 \u0642\u0633\u0645 \u0627\u0644\u0623\u0628\u062d\u0627\u062b \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0648\u0639\u0644\u0645 \u0627\u0644\u0648\u0631\u0627\u062b\u0629 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0641\u064a \u0645\u0631\u0643\u0632 \u0641\u064a\u062a\u0631\u0648\u0631\u064a\u062a\u064a\u0646\u0627\u0644 \u0623\u0633\u0648\u0634\u064a\u062a\u0633 \u0641\u064a \u063a\u064a\u0646\u0632\u0641\u064a\u0644\u060c \u0641\u0644\u0648\u0631\u064a\u062f\u0627\u060c \u062a\u062d\u0644\u064a\u0644\u0627\u062a \u062c\u062f\u064a\u062f\u0629 \u0645\u0633\u062a\u0642\u0627\u0629 \u0645\u0646 \u0645\u062a\u0627\u0628\u0639\u0629 \u0637\u0648\u064a\u0644\u0629 \u0627\u0644\u0623\u0645\u062f \u0644\u0628\u064a\u0627\u0646\u0627\u062a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629\/\u0627\u0644\u062b\u0627\u0644\u062b\u0629 \u0627\u0644\u0639\u0634\u0648\u0627\u0626\u064a\u0629 \u0627\u0644\u062a\u064a \u0627\u0633\u062a\u0645\u0631\u062a \u062b\u0644\u0627\u062b \u0633\u0646\u0648\u0627\u062a\u060c \u0648\u0627\u0644\u062a\u064a \u062a\u062a\u0646\u0627\u0648\u0644 \u062e\u0635\u0627\u0626\u0635 \u0627\u0644\u0645\u0631\u0636\u0649 \u0648\u0627\u0644\u0645\u0631\u0636 \u0627\u0644\u0645\u0631\u062a\u0628\u0637\u0629 \u0628\u0623\u0641\u0636\u0644 \u0627\u0644\u0646\u062a\u0627\u0626\u062c. \u0648\u0647\u0630\u0647 \u0647\u064a \u0627\u0644\u0645\u0631\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0627\u0644\u062a\u064a \u062a\u064f\u0639\u0631\u0636 \u0641\u064a\u0647\u0627 \u0647\u0630\u0647 \u0627\u0644\u0628\u064a\u0627\u0646\u0627\u062a\u060c \u0645\u0645\u0627 \u064a\u0648\u0641\u0631 \u0644\u0644\u0623\u0637\u0628\u0627\u0621 \u0625\u0637\u0627\u0631\u064b\u0627 \u0623\u0643\u062b\u0631 \u0634\u0645\u0648\u0644\u064b\u0627 \u0644\u0641\u0647\u0645 \u0622\u062b\u0627\u0631 \u0627\u0644\u0639\u0644\u0627\u062c \u0628\u062c\u0631\u0639\u0629 \u0648\u0627\u062d\u062f\u0629 \u0645\u0646 MCO-010 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0641\u064a \u0627\u0644\u0628\u0635\u0631.<\/p>

\u062a\u0641\u0627\u0635\u064a\u0644 \u0627\u0644\u0639\u0631\u0636 \u0627\u0644\u062a\u0642\u062f\u064a\u0645\u064a:<\/b><\/p>

\u0645\u0642\u062f\u0645:\u00a0<\/b>\u0643\u0631\u064a\u0633\u062a\u064a\u0646 \u0646. \u0643\u0627\u064a\u060c \u062f\u0643\u062a\u0648\u0631\u0627\u0647 \u0641\u064a \u0627\u0644\u0637\u0628.
\u0639\u0646\u0648\u0627\u0646:\u00a0<\/b>\u0646\u062a\u0627\u0626\u062c \u062a\u062d\u0633\u064a\u0646 \u0627\u0644\u0631\u0624\u064a\u0629 \u0641\u064a \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a: \u062a\u062d\u0644\u064a\u0644 \u0645\u062a\u0639\u062f\u062f \u0627\u0644\u0645\u062a\u063a\u064a\u0631\u0627\u062a \u0645\u0646 \u0628\u064a\u0627\u0646\u0627\u062a RESTORE \u0648REMAIN \u0644\u0645\u062f\u0629 3 \u0633\u0646\u0648\u0627\u062a \u0644\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062c\u064a\u0646\u064a \u0627\u0644\u0628\u0635\u0631\u064a \u0627\u0644\u0648\u0631\u0627\u062b\u064a MCO-010
<\/i>\u062d\u0635\u0629:\u00a0<\/b>\u0627\u0644\u062d\u062b\u0644 \u0627\u0644\u0648\u0631\u0627\u062b\u064a \u0645\u0646 \u0627\u0644\u0646\u0648\u0639 \u0627\u0644\u0623\u0648\u0644: \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0648\u0645\u0627 \u0628\u0639\u062f\u0647\u0627
Date & Time:\u00a0<\/b>\u0627\u0644\u062c\u0645\u0639\u0629\u060c \u0662\u0667 \u0641\u0628\u0631\u0627\u064a\u0631 | \u0667:\u0663\u0660 \u0635\u0628\u0627\u062d\u064b\u0627 - \u0667:\u0663\u0665 \u0635\u0628\u0627\u062d\u064b\u0627<\/p>

“These analyses are an important next step in helping to understand the Phase 3 clinical trial data of MCO-010 in retinitis pigmentosa,” said Dr. Kay.<\/b>\u00a0“By examining the characteristics of patients who had the best outcomes across three years of follow-up in RESTORE and REMAIN, we can begin to understand how the therapy can be used in patients in the real world, if approved.”<\/p>

“Dr. Kay’s multivariant analyses add a clinically significant dimension to what is already a landmark dataset,” said\u00a0<\/b>\u0633\u0627\u0645\u0648\u064a\u0644 \u0628\u0627\u0631\u0648\u0646\u060c \u062f\u0643\u062a\u0648\u0631 \u0641\u064a \u0627\u0644\u0637\u0628.<\/a><\/b>, \u0643\u0628\u064a\u0631 \u0627\u0644\u0645\u0633\u0624\u0648\u0644\u064a\u0646 \u0627\u0644\u0637\u0628\u064a\u064a\u0646 \u0641\u064a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633.<\/b>\u00a0“We are proud to present this work at the Macula Society Annual Meeting, where leading retinal specialists will be able to engage directly with the findings as we continue our rolling BLA for MCO-010 \u2013 potentially offering the first approved therapy for patients with retinitis pigmentosa having severe vision loss.”<\/p>

\u062d\u0648\u0644 \u0645\u0646\u0635\u0629 \u0625\u062f\u0627\u0631\u0629 \u0623\u0648\u0627\u0645\u0631 \u0627\u0644\u0642\u064a\u0627\u062f\u0629
<\/b>MCO \u0639\u0628\u0627\u0631\u0629 \u0639\u0646 \u0645\u0646\u0635\u0629 \u0639\u0644\u0627\u062c\u064a\u0629 \u062a\u064f\u0639\u0637\u0649 \u0644\u0645\u0631\u0629 \u0648\u0627\u062d\u062f\u0629 \u0641\u064a \u0627\u0644\u0639\u064a\u0627\u062f\u0629\u060c \u0648\u062a\u064f\u062d\u0642\u0646 \u062f\u0627\u062e\u0644 \u0627\u0644\u062c\u0633\u0645 \u0627\u0644\u0632\u062c\u0627\u062c\u064a \u0644\u0644\u0634\u0628\u0643\u064a\u0629\u060c \u0648\u0647\u064a \u0645\u0635\u0645\u0645\u0629 \u0644\u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u062f\u0649 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u062a\u0646\u0643\u0633 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u0633\u062a\u0642\u0628\u0644\u0629 \u0644\u0644\u0636\u0648\u0621\u060c \u0628\u0645\u0627 \u0641\u064a \u0630\u0644\u0643 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a (RP) \u0648\u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a (SD) \u0648\u0627\u0644\u0636\u0645\u0648\u0631 \u0627\u0644\u062c\u063a\u0631\u0627\u0641\u064a (GA). \u062a\u0639\u0645\u0644 MCO \u0639\u0644\u0649 \u062a\u0646\u0634\u064a\u0637 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u062b\u0646\u0627\u0626\u064a\u0629 \u0627\u0644\u0642\u0637\u0628 \u0639\u0627\u0644\u064a\u0629 \u0627\u0644\u0643\u062b\u0627\u0641\u0629 \u0641\u064a \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0644\u062a\u0635\u0628\u062d \u062d\u0633\u0627\u0633\u0629 \u0644\u0644\u0636\u0648\u0621\u060c \u0645\u0633\u062a\u0641\u064a\u062f\u0629\u064b \u0645\u0646 \u0627\u0644\u062f\u0648\u0627\u0626\u0631 \u0627\u0644\u0628\u0635\u0631\u064a\u0629 \u0627\u0644\u0645\u062a\u0628\u0642\u064a\u0629 \u0628\u0639\u062f \u0645\u0648\u062a \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u0633\u062a\u0642\u0628\u0644\u0629 \u0644\u0644\u0636\u0648\u0621. \u0644\u0627 \u064a\u062a\u0637\u0644\u0628 \u0639\u0644\u0627\u062c MCO \u0627\u062e\u062a\u0628\u0627\u0631\u0627\u062a \u062c\u064a\u0646\u064a\u0629 \u0623\u0648 \u062c\u0631\u0627\u062d\u0629 \u063a\u0627\u0632\u064a\u0629 \u0623\u0648 \u062c\u0631\u0639\u0627\u062a \u0645\u062a\u0643\u0631\u0631\u0629\u060c \u0645\u0645\u0627 \u064a\u062a\u064a\u062d \u062a\u0637\u0628\u064a\u0642\u0647 \u0639\u0644\u0649 \u0646\u0637\u0627\u0642 \u0648\u0627\u0633\u0639 \u0645\u0646 \u0627\u0644\u0645\u0631\u0636\u0649 \u0636\u0645\u0646 \u0625\u062c\u0631\u0627\u0621\u0627\u062a \u0627\u0644\u0639\u0645\u0644 \u0627\u0644\u062d\u0627\u0644\u064a\u0629 \u0641\u064a \u0639\u064a\u0627\u062f\u0627\u062a \u0627\u0644\u0634\u0628\u0643\u064a\u0629.<\/p>

\u0646\u0628\u0630\u0629 \u0639\u0646 \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633
<\/b>\u062a\u0639\u0645\u0644 \u0634\u0631\u0643\u0629 Nanoscope Therapeutics \u0639\u0644\u0649 \u062a\u0637\u0648\u064a\u0631 \u0639\u0644\u0627\u062c \u0628\u0635\u0631\u064a \u0648\u0631\u0627\u062b\u064a \u0644\u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631\u060c \u0628\u063a\u0636 \u0627\u0644\u0646\u0638\u0631 \u0639\u0646 \u0646\u0648\u0639 \u0627\u0644\u0645\u0631\u0636\u060c \u0644\u0645\u0644\u0627\u064a\u064a\u0646 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u0641\u0642\u062f\u0648\u0627 \u0628\u0635\u0631\u0647\u0645 \u0628\u0633\u0628\u0628 \u0623\u0645\u0631\u0627\u0636 \u062a\u0646\u0643\u0633\u064a\u0629 \u0641\u064a \u0627\u0644\u0634\u0628\u0643\u064a\u0629. \u0648\u0630\u0644\u0643 \u0628\u0639\u062f \u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0625\u064a\u062c\u0627\u0628\u064a\u0629 \u0627\u0644\u062a\u064a \u062d\u0642\u0642\u062a\u0647\u0627 \u062a\u062c\u0631\u0628\u0629 RESTORE \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u0645\u0631\u0627\u0643\u0632\u060c \u0627\u0644\u0639\u0634\u0648\u0627\u0626\u064a\u0629\u060c \u0645\u0632\u062f\u0648\u062c\u0629 \u0627\u0644\u062a\u0639\u0645\u064a\u0629\u060c \u0648\u0627\u0644\u0645\u0636\u0628\u0648\u0637\u0629 \u0628\u0627\u0644\u063a\u0641\u0644\u060c \u0645\u0646 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 2\u0628\/3\u060c \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a (RP).NCT04945772<\/a>\u0644\u0627 \u064a\u0632\u0627\u0644 \u062a\u0642\u062f\u064a\u0645 \u0637\u0644\u0628 \u062a\u0631\u062e\u064a\u0635 \u0627\u0644\u0645\u0646\u062a\u062c \u0627\u0644\u0628\u064a\u0648\u0644\u0648\u062c\u064a (BLA) \u0625\u0644\u0649 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 (FDA) \u062c\u0627\u0631\u064a\u0627\u064b. \u0641\u064a \u062d\u0627\u0644 \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629 \u0639\u0644\u064a\u0647\u060c \u064a\u064f\u062d\u062a\u0645\u0644 \u0623\u0646 \u064a\u0635\u0628\u062d MCO-010 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0642\u064a\u0627\u0633\u064a \u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a (RP)\u060c \u062d\u064a\u062b \u064a\u064f\u0639\u0637\u0649 \u0643\u062d\u0642\u0646\u0629 \u0648\u0627\u062d\u062f\u0629 \u0641\u064a \u0627\u0644\u0639\u064a\u0627\u062f\u0629 \u062f\u0648\u0646 \u0627\u0644\u062d\u0627\u062c\u0629 \u0625\u0644\u0649 \u0627\u062e\u062a\u0628\u0627\u0631\u0627\u062a \u062c\u064a\u0646\u064a\u0629. \u0643\u0645\u0627 \u0623\u0638\u0647\u0631\u062a \u0627\u0644\u0634\u0631\u0643\u0629 \u0646\u062a\u0627\u0626\u062c \u0648\u0627\u0639\u062f\u0629 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 STARLIGHT \u0644\u0640 MCO-010 \u0641\u064a \u0639\u0644\u0627\u062c \u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a (SD).NCT05417126<\/a>) \u0648\u062a\u062e\u0637\u0637 \u0644\u0628\u062f\u0621\u00a0\u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0644\u062b\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u062a\u0633\u062c\u064a\u0644\u064a\u0629<\/a>\u00a0\u0641\u064a \u0639\u0627\u0645 2026\u060c \u062d\u0635\u0644 \u062f\u0648\u0627\u0621 MCO-010 \u0639\u0644\u0649 \u062a\u0635\u0646\u064a\u0641 \u0627\u0644\u0645\u0633\u0627\u0631 \u0627\u0644\u0633\u0631\u064a\u0639 \u0648\u062a\u0635\u0646\u064a\u0641 \u062f\u0648\u0627\u0621 \u0627\u0644\u064a\u062a\u064a\u0645 \u0645\u0646 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0644\u0639\u0644\u0627\u062c \u0643\u0644 \u0645\u0646 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a (RP) \u0648\u0645\u0631\u0636 \u0636\u0645\u0648\u0631 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 (SD)\u060c \u0628\u0627\u0644\u0625\u0636\u0627\u0641\u0629 \u0625\u0644\u0649 \u062a\u0635\u0646\u064a\u0641 RMAT \u0644\u0645\u0631\u0636 \u0636\u0645\u0648\u0631 \u0627\u0644\u0634\u0628\u0643\u064a\u0629\u060c \u0648\u062a\u0635\u0646\u064a\u0641\u0627\u062a \u062f\u0648\u0627\u0621 \u0627\u0644\u064a\u062a\u064a\u0645 \u0645\u0646 \u0648\u0643\u0627\u0644\u0629 \u0627\u0644\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 (EMA) \u0644\u062a\u063a\u0637\u064a\u0629 \u0636\u0645\u0648\u0631 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u063a\u064a\u0631 \u0627\u0644\u0645\u062a\u0644\u0627\u0632\u0645\u064a \u0648\u0627\u0644\u0645\u062a\u0644\u0627\u0632\u0645\u064a \u0627\u0644\u0630\u064a \u064a\u0647\u064a\u0645\u0646 \u0641\u064a\u0647 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0639\u0635\u0648\u064a\u0629 \u0648\u0627\u0644\u0645\u062e\u0631\u0648\u0637\u064a\u0629\u060c \u0628\u0627\u0644\u0625\u0636\u0627\u0641\u0629 \u0625\u0644\u0649 \u0636\u0645\u0648\u0631 \u0627\u0644\u0628\u0642\u0639\u0629 \u0627\u0644\u0635\u0641\u0631\u0627\u0621. \u0643\u0645\u0627 \u062d\u0635\u0644 MCO-010 \u0639\u0644\u0649 \u062a\u0635\u0646\u064a\u0641 \u0633\u0627\u0643\u064a\u063a\u0627\u0643\u064a (\u0627\u0644\u0631\u0627\u0626\u062f\u0629) \u0648\u062a\u0635\u0646\u064a\u0641 \u062f\u0648\u0627\u0621 \u0627\u0644\u064a\u062a\u064a\u0645 \u0641\u064a \u0627\u0644\u064a\u0627\u0628\u0627\u0646 \u0645\u0646 \u0648\u0632\u0627\u0631\u0629 \u0627\u0644\u0635\u062d\u0629 \u0648\u0627\u0644\u0639\u0645\u0644 \u0648\u0627\u0644\u0631\u0641\u0627\u0647\u064a\u0629. \u0648\u0645\u0646 \u0627\u0644\u0645\u062a\u0648\u0642\u0639 \u0623\u064a\u0636\u064b\u0627 \u0628\u062f\u0621 \u0628\u0631\u0646\u0627\u0645\u062c \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0644\u062f\u0648\u0627\u0621 MCO \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0636\u0645\u0648\u0631 \u0627\u0644\u062c\u063a\u0631\u0627\u0641\u064a (GA) \u0641\u064a \u0639\u0627\u0645 2026. \u0648\u062a\u0634\u0645\u0644 \u0627\u0644\u0628\u0631\u0627\u0645\u062c \u0627\u0644\u0623\u062e\u0631\u0649 \u0627\u0644\u062c\u0627\u0647\u0632\u0629 \u0644\u062a\u0642\u062f\u064a\u0645 \u0637\u0644\u0628\u0627\u062a \u0627\u0644\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u062c\u062f\u064a\u062f\u0629 (IND) \u0639\u0644\u0627\u062c \u0627\u0644\u0639\u0645\u0649 \u0627\u0644\u062e\u0644\u0642\u064a \u0644\u0644\u064a\u0628\u0631 (LCA).<\/p>

\u0627\u062a\u0635\u0627\u0644:
<\/b>\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633
(817) 857-1186
PR@nanostherapeutics.com<\/a><\/p>

\u0627\u0644\u0645\u0635\u062f\u0631 \u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Dr. Christine N. Kay to Present Multivariant Analysis of 3-Year RESTORE and REMAIN Data,\u00a0Identifying Patient and Disease Characteristics Associated with Best Outcomes in Retinitis Pigmentosa Patients Following MCO-010 Optogenetic Gene Therapy DALLAS,\u00a0Feb. 24, 2026\u00a0 — Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and […]<\/p>\n","protected":false},"author":1,"featured_media":10062,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10061","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ar\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"ar_AR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ar\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-24T12:42:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-24T12:49:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 \u062f\u0642\u0627\u0626\u0642\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting\",\"datePublished\":\"2026-02-24T12:42:08+00:00\",\"dateModified\":\"2026-02-24T12:49:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/\"},\"wordCount\":625,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_2026_Macula-Society_REV3.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ar\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/\",\"name\":\"Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_2026_Macula-Society_REV3.jpg\",\"datePublished\":\"2026-02-24T12:42:08+00:00\",\"dateModified\":\"2026-02-24T12:49:19+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_2026_Macula-Society_REV3.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_2026_Macula-Society_REV3.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/02\\\/24\\\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ar\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u0633\u064a\u062a\u0645 \u0639\u0631\u0636 \u0627\u0644\u062a\u062d\u0644\u064a\u0644\u0627\u062a \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0627\u0644\u0644\u0627\u062d\u0642\u0629 \u0644\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0628\u0642\u0639\u0629 \u0627\u0644\u0635\u0641\u0631\u0627\u0621 \u0644\u0639\u0627\u0645 2026 - \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","description":"\u062a\u064f\u0639\u062f\u0651 \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0648\u0628\u0633\u064a\u0646 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062e\u0635\u0627\u0626\u0635 (MCO) \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0646\u0627 \u0627\u0644\u0623\u0648\u0644\u0649 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0627\u0644\u062a\u064a \u0623\u062b\u0628\u062a\u062a \u0642\u062f\u0631\u062a\u0647\u0627 \u0639\u0644\u0649 \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u0645\u0631\u0636\u0649 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629. \u0648\u0642\u062f \u0637\u0648\u0651\u0631\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0642\u0646\u064a\u0629 MCO-010\u060c \u0648\u0647\u064a \u0627\u0644\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u0629 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0641\u064a \u0645\u062c\u0627\u0644 \u0639\u0644\u0645 \u0627\u0644\u0628\u0635\u0631\u064a\u0627\u062a \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u062a\u062a\u0645\u064a\u0632 \u0628\u0646\u0637\u0627\u0642\u0647\u0627 \u0627\u0644\u0648\u0627\u0633\u0639 \u0648\u0627\u0633\u062a\u062c\u0627\u0628\u062a\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0648\u062d\u0633\u0627\u0633\u064a\u062a\u0647\u0627 \u0627\u0644\u0641\u0627\u0626\u0642\u0629\u060c \u0648\u0647\u064a \u062a\u0642\u0646\u064a\u0629 \u0645\u0633\u062a\u0642\u0644\u0629 \u0639\u0646 \u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0627\u0644\u0645\u0633\u062a\u062e\u062f\u0645\u0629 \u0641\u064a \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ar\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/","og_locale":"ar_AR","og_type":"article","og_title":"Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ar\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-02-24T12:42:08+00:00","article_modified_time":"2026-02-24T12:49:19+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629":"Wilson PJ","\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631":"3 \u062f\u0642\u0627\u0626\u0642"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting","datePublished":"2026-02-24T12:42:08+00:00","dateModified":"2026-02-24T12:49:19+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/"},"wordCount":625,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_2026_Macula-Society_REV3.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ar"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/","url":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/","name":"\u0633\u064a\u062a\u0645 \u0639\u0631\u0636 \u0627\u0644\u062a\u062d\u0644\u064a\u0644\u0627\u062a \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0627\u0644\u0644\u0627\u062d\u0642\u0629 \u0644\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u0641\u064a \u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u062c\u0645\u0639\u064a\u0629 \u0627\u0644\u0628\u0642\u0639\u0629 \u0627\u0644\u0635\u0641\u0631\u0627\u0621 \u0644\u0639\u0627\u0645 2026 - \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_2026_Macula-Society_REV3.jpg","datePublished":"2026-02-24T12:42:08+00:00","dateModified":"2026-02-24T12:49:19+00:00","description":"\u062a\u064f\u0639\u062f\u0651 \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0648\u0628\u0633\u064a\u0646 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062e\u0635\u0627\u0626\u0635 (MCO) \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0646\u0627 \u0627\u0644\u0623\u0648\u0644\u0649 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0627\u0644\u062a\u064a \u0623\u062b\u0628\u062a\u062a \u0642\u062f\u0631\u062a\u0647\u0627 \u0639\u0644\u0649 \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u0645\u0631\u0636\u0649 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629. \u0648\u0642\u062f \u0637\u0648\u0651\u0631\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0642\u0646\u064a\u0629 MCO-010\u060c \u0648\u0647\u064a \u0627\u0644\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u0629 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0641\u064a \u0645\u062c\u0627\u0644 \u0639\u0644\u0645 \u0627\u0644\u0628\u0635\u0631\u064a\u0627\u062a \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u062a\u062a\u0645\u064a\u0632 \u0628\u0646\u0637\u0627\u0642\u0647\u0627 \u0627\u0644\u0648\u0627\u0633\u0639 \u0648\u0627\u0633\u062a\u062c\u0627\u0628\u062a\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0648\u062d\u0633\u0627\u0633\u064a\u062a\u0647\u0627 \u0627\u0644\u0641\u0627\u0626\u0642\u0629\u060c \u0648\u0647\u064a \u062a\u0642\u0646\u064a\u0629 \u0645\u0633\u062a\u0642\u0644\u0629 \u0639\u0646 \u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0627\u0644\u0645\u0633\u062a\u062e\u062f\u0645\u0629 \u0641\u064a \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/#breadcrumb"},"inLanguage":"ar","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_2026_Macula-Society_REV3.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_2026_Macula-Society_REV3.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/02\/24\/nanoscope-therapeutics-post-hoc-clinical-analyses-to-be-presented-at-2026-macula-society-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628","description":"\u0625\u0639\u0627\u062f\u0629 \u0646\u0648\u0631 \u0627\u0644\u0623\u0645\u0644","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ar"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"\u0648\u064a\u0644\u0633\u0648\u0646 \u0628\u064a \u062c\u064a\u0647"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/10061","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/comments?post=10061"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/10061\/revisions"}],"predecessor-version":[{"id":10066,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/10061\/revisions\/10066"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/media\/10062"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/media?parent=10061"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/categories?post=10061"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/tags?post=10061"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}